PDCD1 and non-small cell lung carcinoma: This pooled analysis included seven studies which evaluated the ORR of patients with NSCLC treated with anti PD1/PD-L1 MoAbs who received prior chemotherapy regimens stratified according to the tumor PD-L1 expression status (IHC, cut-off point 1%).